Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ERNA
ERNA | US
8.00
USD-1.12
-12.28%
ERNA | US
About ERNA
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
8.00
Open
9.08
High
9.10
Low
8.00
Eterna Therapeutics Inc. a preclinical-stage biopharmaceutical company. The company offers Synthetic mRNA ToRNAdo mRNA Delivery mRNA Gene Editing and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology blood disorder and monogenic disease. The company was formerly known as and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge Massachusetts.
View LessERNA | US
Risk
361.2
Sharpe
0.05
Luna's Score
42/100
Recommendation
Sell
Luna says (ERNA | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
114.1%1 month
361.2%3 months
4980.2%6 months
3567.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.10
Debt to equity
-5.77
Debt to assets
1.06
Ent. to EBITDA
-0.29
Ent. to rev.
321.84
PEG
-
Other Fundamentals
EBITDA
-21.86M
MarketCap
43.28M
MarketCap(USD)
43.28M
Div. yield
-
Op. margin
-10.49K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.15K
Short ratio
1.01
Short perc.
1.32
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
5.00
Range1M
12.70
Range3M
15.75
Volumes: Market Activity
Rel. volume
0.01
Price X volume
429.30K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.29 | - | Cheaper |
| Ent. to Revenue | 321.84 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 4,980.24 | - | Riskier |
| Debt to Equity | -5.77 | -1.23 | Cheaper |
| Debt to Assets | 1.06 | 0.25 | Expensive |
| Market Cap | 43.28M | - | Emerging |
